Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers.

Oncology reports·2019
Same author

Synthesis and antiproliferative action of a novel series of maprotiline analogues.

European journal of medicinal chemistry·2013
Same author

Designed multiple ligands for cancer therapy.

Current medicinal chemistry·2011
Same author

Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.

Current medicinal chemistry·2008
Same author

Recent advances in estrogen receptor antagonists.

IDrugs : the investigational drugs journal·2005
Same author

Advances in the science of estrogen receptor modulation.

Current medicinal chemistry·2003

Related Experiment Video

Updated: Jun 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting tumors using estrogen receptor ligand conjugates.

N O Keely1, M J Meegan

  • 1School of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College, Dublin 2, Ireland.

Current Cancer Drug Targets
|May 16, 2009
PubMed
Summary

Targeting cancer with estrogen receptor ligand conjugates offers a promising approach to improve chemotherapy. These targeted agents enhance specificity, potentially reducing side effects and improving treatment efficacy for hormone-dependent cancers.

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Related Experiment Videos

Last Updated: Jun 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Cytotoxic chemotherapy agents often lack specificity, leading to toxicity and side effects.
  • Tumor targeting strategies exploit differences between cancer and healthy tissues for selective drug delivery.
  • Estrogen receptors are over-expressed in certain hormone-dependent cancers, presenting a target for selective therapies.

Purpose of the Study:

  • To review developments in estrogen receptor ligand conjugates for targeted cancer chemotherapy.
  • To highlight the potential of these conjugates in improving chemotherapeutic treatments.

Main Methods:

  • Review of literature on estrogen receptor ligand conjugates.
  • Investigation of conjugates incorporating cytotoxic agents, photodynamic therapies, and radioligands.
  • Analysis of studies focused on improving pharmaceutical properties of these conjugates.

Main Results:

  • Structurally varied estrogen receptor ligand conjugates have been developed.
  • Conjugates demonstrated potential for targeting estrogen receptor-over-expressing tumors.
  • Studies showed promising results in enhancing pharmaceutical properties of these targeted agents.

Conclusions:

  • Estrogen receptor ligand conjugates represent a viable strategy for developing more effective and selective cancer chemotherapy.
  • Targeted approaches using these conjugates may lead to improved therapeutic outcomes with reduced toxicity.
  • Further research into these conjugates holds potential for advancing cancer treatment discovery.